• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis

    10/28/24 8:00:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KNSA alert in real time by email

    – National campaign to elevate experiences from the recurrent pericarditis community and empower patients to seek care –

    LONDON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a commercial-stage biopharmaceutical company, with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced a partnership with GRAMMY Award-winning singer-songwriter, Carly Pearce, as part of its Life DisRPted campaign focused on promoting early diagnosis and treatment of recurrent pericarditis. Pearce announced that she had been diagnosed with the chronic autoinflammatory disease while on tour in May 2024.

    "We are excited to have Carly Pearce join our Life DisRPted campaign in support of the patients and caregivers facing recurrent pericarditis, a rare, chronic, flaring disease that is too often undertreated," said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. "With this campaign, we continue to provide a clear call to action for both patients and healthcare providers to seek out the signs of recurrent pericarditis and develop a treatment plan to minimize the impact it has on patient lives."

    To learn about recurrent pericarditis and the Life DisRPted campaign, visit LifeDisRPted.com.

    About Recurrent Pericarditis

    Recurrent pericarditis is a painful and debilitating chronic autoinflammatory cardiovascular disease marked by inflammation of the pericardium and is often associated with changes in electrical conduction and sometimes buildup of fluid around the heart, called pericardial effusion. Recurrent pericarditis symptoms have an impact on quality of life, limit physical activities, and lead to frequent emergency department visits and hospitalizations. Data show that approximately 40,000 patients in the U.S. seek and receive treatment for recurrent pericarditis each year. Of that group, approximately 14,000 patients experience two or more recurrences due to persistent underlying disease or inadequate response to conventional therapies, such as nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine and corticosteroids.

    About Kiniksa

    Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's immune-modulating assets are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.

    About Carly Pearce

    Fiercely rooted in the classics, GRAMMY® Award-winning singer-songwriter Carly Pearce lit a fire with her debut album Every Little Thing and the PLATINUM-certified history-making title track, and she hasn't slowed down since. With the praised release of her highly anticipated fourth album, hummingbird (June 7, Big Machine Records), Pearce continues to resonate with her honest lyrics and timeless musicality. The critically acclaimed album includes lead single "we don't fight anymore" (featuring Chris Stapleton), which earned Pearce her second GRAMMY® nomination for Best Country Duo/Group Performance and fifth Top 5 Country Radio hit. Pearce is currently performing the new music on her headlining hummingbird world tour. Previously, her critically acclaimed and commercially lauded third studio album 29 produced Country Radio chart toppers including "Never Wanted To Be That Girl" with Ashley McBryde which gave Pearce her second consecutive ACM Music Event of the Year in 2022 and marked the third duet between two solo women to top Billboard's Country Airplay chart. The song also took home the 2022 CMA Musical Event of the Year and won a GRAMMY® Award for Best Country Duo/Group Performance, marking Pearce's first, and making history as the first female pairing to win in the category. In addition, Pearce's 3x PLATINUM-certified "I Hope You're Happy Now" with Lee Brice won both the 2020 CMA Awards Musical Event and 2021 ACM Awards Music Event, plus ACM Single of the Year. Both a Grand Ole Opry and Kentucky Music Hall of Fame member, Pearce has since made her 100th performance at the Grand Ole Opry. For more information, visit CarlyPearce.com.

    Every Second Counts! ®

    Kiniksa Investor Contact

    Jonathan Kirshenbaum

    (781) 829-3949

    [email protected]

    Kiniksa Media Contact

    Tyler Gagnon

    (781) 431-9100

    [email protected]

    Carly Pearce Media Contacts

    Erica Gerard

    [email protected]

    Avery Robinson

    [email protected]



    Primary Logo

    Get the next $KNSA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What recent partnership did Kiniksa Pharmaceuticals enter into, and what is its purpose?

      Kiniksa Pharmaceuticals announced a partnership with Carly Pearce to promote the early diagnosis and treatment of recurrent pericarditis.

    • What is recurrent pericarditis and how does it affect patients?

      Recurrent pericarditis is a chronic autoinflammatory disease that causes pain and inflammation of the pericardium, which can lead to complications like pericardial effusion.

    • How many patients in the U.S. are affected by recurrent pericarditis annually?

      Approximately 40,000 patients in the U.S. seek treatment for recurrent pericarditis each year, with around 14,000 experiencing multiple recurrences.

    • When was Carly Pearce diagnosed with recurrent pericarditis, and how does she plan to raise awareness about this condition?

      Carly Pearce was diagnosed with recurrent pericarditis while on her tour in May 2024, and she is using her experience to help raise awareness through the Life DisRPted campaign.

    • What is the objective of the Life DisRPted campaign launched by Kiniksa Pharmaceuticals?

      The Life DisRPted campaign aims to empower patients and caregivers to recognize signs of recurrent pericarditis and to advocate for better treatment options.

    Recent Analyst Ratings for
    $KNSA

    DatePrice TargetRatingAnalyst
    2/19/2026$62.00Buy
    Canaccord Genuity
    9/29/2025$60.00Buy
    TD Cowen
    3/13/2025$40.00Buy
    Citigroup
    9/13/2024$40.00Buy
    Jefferies
    5/3/2024$34.00Overweight
    Wells Fargo
    12/29/2021$37.00 → $34.00Buy
    B of A Securities
    More analyst ratings

    $KNSA
    SEC Filings

    View All

    SEC Form DEFA14A filed by Kiniksa Pharmaceuticals International plc

    DEFA14A - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)

    4/16/26 4:33:04 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Kiniksa Pharmaceuticals International plc

    DEF 14A - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)

    4/16/26 4:32:18 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Kiniksa Pharmaceuticals International plc

    144 - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    4/9/26 4:02:53 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Megna Michael R

    4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

    4/13/26 4:35:46 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Moat Ross

    4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

    4/13/26 4:34:42 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Tessari Eben

    4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

    4/8/26 4:45:11 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Kiniksa Pharmaceuticals with a new price target

    Canaccord Genuity initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $62.00

    2/19/26 7:51:41 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Kiniksa Pharmaceuticals with a new price target

    TD Cowen initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $60.00

    9/29/25 9:58:02 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Kiniksa Pharmaceuticals with a new price target

    Citigroup initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    3/13/25 7:43:42 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis

    – Educational campaign to raise awareness of recurrent pericarditis and to empower patients to discuss ARCALYST with their healthcare provider – – Media accompanying this announcement is available by clicking on this link – LONDON, April 08, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today announced the launch of Heart's Home™, a Direct-to-Consumer (DTC) campaign for ARCALYST, the first-and-only U.S. Food and Drug Administration (FDA) approved therapy for recurrent pericarditis. This multi-fa

    4/8/26 8:00:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference

    LONDON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 3:10 p.m. Eastern Time. A live webcast of Kiniksa's presentation will be accessible through the Investors section of the company's website at www.kiniksa.com. A replay of the event will also be available on Kiniksa's website within approximately 48 hours after the event. About KiniksaKiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and c

    2/25/26 4:01:00 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution

    – ARCALYST® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 –– KPL-1161 Phase 1 trial planned to initiate by the end of 2026 –– Cash balance increased by $170.4 million in 2025 to $414.1 million –      – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Feb. 24, 2026 (GLOBE NEWSWIRE) --  – Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus

    2/24/26 7:30:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Financials

    Live finance-specific insights

    View All

    Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution

    – ARCALYST® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 –– KPL-1161 Phase 1 trial planned to initiate by the end of 2026 –– Cash balance increased by $170.4 million in 2025 to $414.1 million –      – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Feb. 24, 2026 (GLOBE NEWSWIRE) --  – Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus

    2/24/26 7:30:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

    LONDON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 24, 2026 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique p

    2/19/26 4:01:00 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution

    – ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net product revenue raised to $670 - $675 million –– KPL-387 granted Orphan Drug Designation for the treatment of pericarditis – – Cash balance increased by $44.3 million in Q3 2025 to $352.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported third quarter 202

    10/28/25 7:30:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

    SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    11/14/24 4:32:31 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

    SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    11/14/24 4:15:22 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

    SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    11/13/24 4:30:25 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care